

Robert Roskoski

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2327987/robert-roskoski-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53
papers

9,980
citations

41
h-index

58
g-index

58
ext. papers

11,744
ext. citations

7.6
avg, IF

8.17
L-index

#	Paper	IF	Citations
53	ERK1/2 MAP kinases: structure, function, and regulation. <i>Pharmacological Research</i> , 2012 , 66, 105-43	10.2	939
52	The ErbB/HER family of protein-tyrosine kinases and cancer. <i>Pharmacological Research</i> , 2014 , 79, 34-74	10.2	750
51	Assays of protein kinase. <i>Methods in Enzymology</i> , 1983 , 99, 3-6	1.7	740
50	Vascular endothelial growth factor (VEGF) signaling in tumor progression. <i>Critical Reviews in Oncology/Hematology</i> , 2007 , 62, 179-213	7	442
49	Src kinase regulation by phosphorylation and dephosphorylation. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 331, 1-14	3.4	442
48	Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. <i>Pharmacological Research</i> , 2016 , 103, 26-48	10.2	397
47	Src protein-tyrosine kinase structure and regulation. <i>Biochemical and Biophysical Research Communications</i> , 2004 , 324, 1155-64	3.4	385
46	Adenosine cyclic 3',5'-monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit. <i>Biochemistry</i> , 1982 , 21, 5794-9	3.2	371
45	Rapid protein kinase assay using phosphocellulose-paper absorption. <i>Analytical Biochemistry</i> , 1975 , 66, 253-8	3.1	332
44	The ErbB/HER receptor protein-tyrosine kinases and cancer. <i>Biochemical and Biophysical Research Communications</i> , 2004 , 319, 1-11	3.4	309
43	Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. <i>Biochemical and Biophysical Research Communications</i> , 2007 , 356, 323-8	3.4	295
42	A historical overview of protein kinases and their targeted small molecule inhibitors. <i>Pharmacological Research</i> , 2015 , 100, 1-23	10.2	288
41	Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. <i>Pharmacological Research</i> , 2015 , 94, 9-25	10.2	287
40	Properties of FDA-approved small molecule protein kinase inhibitors. <i>Pharmacological Research</i> , 2019 , 144, 19-50	10.2	247
39	Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 338, 1307-15	3.4	246
38	Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. <i>Pharmacological Research</i> , 2020 , 152, 104609	10.2	244
37	RAF protein-serine/threonine kinases: structure and regulation. <i>Biochemical and Biophysical Research Communications</i> , 2010 , 399, 313-7	3.4	242

36	Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 337, 1-13	3-4	221
35	Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. <i>Pharmacological Research</i> , 2016 , 111, 784-803	10.2	203
34	VEGF receptor protein-tyrosine kinases: structure and regulation. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 375, 287-91	3-4	195
33	Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. <i>Pharmacological Research</i> , 2019 , 139, 395-411	10.2	194
32	Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. <i>Pharmacological Research</i> , 2013 , 68, 68-94	10.2	186
31	MEK1/2 dual-specificity protein kinases: structure and regulation. <i>Biochemical and Biophysical Research Communications</i> , 2012 , 417, 5-10	3-4	172
30	Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. <i>Pharmacological Research</i> , 2019 , 139, 471-488	10.2	168
29	Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. <i>Pharmacological Research</i> , 2017 , 120, 116-132	10.2	141
28	ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. <i>Pharmacological Research</i> , 2014 , 87, 42-59	10.2	133
27	Protein prenylation: a pivotal posttranslational process. <i>Biochemical and Biophysical Research Communications</i> , 2003 , 303, 1-7	3-4	133
26	Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. <i>Pharmacological Research</i> , 2016 , 107, 249-275	10.2	122
25	Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. <i>Pharmacological Research</i> , 2021 , 165, 105463	10.2	107
24	Targeting ERK1/2 protein-serine/threonine kinases in human cancers. <i>Pharmacological Research</i> , 2019 , 142, 151-168	10.2	100
23	Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. <i>Pharmacological Research</i> , 2018 , 135, 239-258	10.2	89
22	STI-571: an anticancer protein-tyrosine kinase inhibitor. <i>Biochemical and Biophysical Research Communications</i> , 2003 , 309, 709-17	3-4	83
21	Complex molecular regulation of tyrosine hydroxylase. <i>Journal of Neural Transmission</i> , 2014 , 121, 1451-813	3-4	76
20	Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. <i>Pharmacological Research</i> , 2017 , 117, 343-356	10.2	69
19	The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders. <i>Pharmacological Research</i> , 2018 , 129, 65-83	10.2	68

18	ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. <i>Pharmacological Research</i> , 2017 , 121, 202-212	10.2	67
17	Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. <i>Pharmacological Research</i> , 2016 , 113, 395-408	10.2	59
16	Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. <i>Pharmacological Research</i> , 2017 , 117, 20-31	10.2	58
15	Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. <i>Pharmacological Research</i> , 2018 , 128, 1-17	10.2	58
14	The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. <i>Pharmacological Research</i> , 2018 , 133, 35-52	10.2	45
13	The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. <i>Pharmacological Research</i> , 2020 , 151, 104567	10.2	39
12	Role of the carboxyterminal residue in peptide binding to protein farnesyltransferase and protein geranylgeranyltransferase. <i>Archives of Biochemistry and Biophysics</i> , 1998 , 356, 167-76	4.1	33
11	The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders. <i>Expert Opinion on Drug Discovery</i> , 2013 , 8, 1165-79	6.2	26
10	Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update.. <i>Pharmacological Research</i> , 2021 , 106037	10.2	22
9	Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs). <i>Pharmacological Research</i> , 2021 , 165, 105422	10.2	15
8	Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. <i>Pharmacological Research</i> , 2021 , 168, 105579	10.2	13
7	The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias. <i>Pharmacological Research</i> , 2020 , 155, 104725	10.2	8
6	NIH funding trends to US medical schools from 2009 to 2018. <i>PLoS ONE</i> , 2020 , 15, e0233367	3.7	7
5	Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes. <i>Pharmacological Research</i> , 2021 , 169, 105660	10.2	7
4	Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS. <i>Pharmacological Research</i> , 2021 , 172, 105806	10.2	7
3	Michaelis-Menten Kinetics 2015 ,		6
2	Fritz Lipmann (1899-1986): an appreciation. <i>Trends in Biochemical Sciences</i> , 1987 , 12, 136-138	10.3	3
1	Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia.. <i>Pharmacological Research</i> , 2022 , 178, 106156	10.2	2

